BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 32035657)

  • 1. Inhibitors Targeting RIPK1/RIPK3: Old and New Drugs.
    Martens S; Hofmans S; Declercq W; Augustyns K; Vandenabeele P
    Trends Pharmacol Sci; 2020 Mar; 41(3):209-224. PubMed ID: 32035657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FKBP12 mediates necroptosis by initiating RIPK1-RIPK3-MLKL signal transduction in response to TNF receptor 1 ligation.
    Wang Z; Feng J; Yu J; Chen G
    J Cell Sci; 2019 May; 132(10):. PubMed ID: 31028177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neurotoxicant PCB-95 by increasing the neuronal transcriptional repressor REST down-regulates caspase-8 and increases Ripk1, Ripk3 and MLKL expression determining necroptotic neuronal death.
    Guida N; Laudati G; Serani A; Mascolo L; Molinaro P; Montuori P; Di Renzo G; Canzoniero LMT; Formisano L
    Biochem Pharmacol; 2017 Oct; 142():229-241. PubMed ID: 28676433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Inflammatory Signal Adaptor RIPK3: Functions Beyond Necroptosis.
    Moriwaki K; Chan FK
    Int Rev Cell Mol Biol; 2017; 328():253-275. PubMed ID: 28069136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. K45A mutation of RIPK1 results in poor necroptosis and cytokine signaling in macrophages, which impacts inflammatory responses in vivo.
    Shutinoski B; Alturki NA; Rijal D; Bertin J; Gough PJ; Schlossmacher MG; Sad S
    Cell Death Differ; 2016 Oct; 23(10):1628-37. PubMed ID: 27258786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the Raf kinase inhibitor TAK-632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3.
    Chen X; Zhuang C; Ren Y; Zhang H; Qin X; Hu L; Fu J; Miao Z; Chai Y; Liu ZG; Zhang H; Cai Z; Wang HY
    Br J Pharmacol; 2019 Jun; 176(12):2095-2108. PubMed ID: 30825190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.
    Hou J; Ju J; Zhang Z; Zhao C; Li Z; Zheng J; Sheng T; Zhang H; Hu L; Yu X; Zhang W; Li Y; Wu M; Ma H; Zhang X; He S
    Cell Death Dis; 2019 Jun; 10(7):493. PubMed ID: 31235688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RIPK1 inhibits ZBP1-driven necroptosis during development.
    Newton K; Wickliffe KE; Maltzman A; Dugger DL; Strasser A; Pham VC; Lill JR; Roose-Girma M; Warming S; Solon M; Ngu H; Webster JD; Dixit VM
    Nature; 2016 Dec; 540(7631):129-133. PubMed ID: 27819682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caspase-8, receptor-interacting protein kinase 1 (RIPK1), and RIPK3 regulate retinoic acid-induced cell differentiation and necroptosis.
    Someda M; Kuroki S; Miyachi H; Tachibana M; Yonehara S
    Cell Death Differ; 2020 May; 27(5):1539-1553. PubMed ID: 31659279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis.
    Newton K; Dugger DL; Wickliffe KE; Kapoor N; de Almagro MC; Vucic D; Komuves L; Ferrando RE; French DM; Webster J; Roose-Girma M; Warming S; Dixit VM
    Science; 2014 Mar; 343(6177):1357-60. PubMed ID: 24557836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RIPK1 and RIPK3: critical regulators of inflammation and cell death.
    Newton K
    Trends Cell Biol; 2015 Jun; 25(6):347-53. PubMed ID: 25662614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
    Newton K; Dugger DL; Maltzman A; Greve JM; Hedehus M; Martin-McNulty B; Carano RA; Cao TC; van Bruggen N; Bernstein L; Lee WP; Wu X; DeVoss J; Zhang J; Jeet S; Peng I; McKenzie BS; Roose-Girma M; Caplazi P; Diehl L; Webster JD; Vucic D
    Cell Death Differ; 2016 Sep; 23(9):1565-76. PubMed ID: 27177019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Necroptosis in development and diseases.
    Shan B; Pan H; Najafov A; Yuan J
    Genes Dev; 2018 Mar; 32(5-6):327-340. PubMed ID: 29593066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Receptor Interacting Protein Kinases in the Liver.
    Dara L
    Semin Liver Dis; 2018 Feb; 38(1):73-86. PubMed ID: 29471568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RIPK1 can function as an inhibitor rather than an initiator of RIPK3-dependent necroptosis.
    Kearney CJ; Cullen SP; Clancy D; Martin SJ
    FEBS J; 2014 Nov; 281(21):4921-34. PubMed ID: 25195660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Bcr-Abl inhibitor GNF-7 inhibits necroptosis and ameliorates acute kidney injury by targeting RIPK1 and RIPK3 kinases.
    Qin X; Hu L; Shi SN; Chen X; Zhuang C; Zhang W; Jitkaew S; Pang X; Yu J; Tan YX; Wang HY; Cai Z
    Biochem Pharmacol; 2020 Jul; 177():113947. PubMed ID: 32247850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RIPK1/RIPK3 promotes vascular permeability to allow tumor cell extravasation independent of its necroptotic function.
    Hänggi K; Vasilikos L; Valls AF; Yerbes R; Knop J; Spilgies LM; Rieck K; Misra T; Bertin J; Gough PJ; Schmidt T; de Almodòvar CR; Wong WW
    Cell Death Dis; 2017 Feb; 8(2):e2588. PubMed ID: 28151480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis.
    Rickard JA; O'Donnell JA; Evans JM; Lalaoui N; Poh AR; Rogers T; Vince JE; Lawlor KE; Ninnis RL; Anderton H; Hall C; Spall SK; Phesse TJ; Abud HE; Cengia LH; Corbin J; Mifsud S; Di Rago L; Metcalf D; Ernst M; Dewson G; Roberts AW; Alexander WS; Murphy JM; Ekert PG; Masters SL; Vaux DL; Croker BA; Gerlic M; Silke J
    Cell; 2014 May; 157(5):1175-88. PubMed ID: 24813849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death.
    Moriwaki K; Bertin J; Gough PJ; Orlowski GM; Chan FK
    Cell Death Dis; 2015 Feb; 6(2):e1636. PubMed ID: 25675296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting RIPK1 kinase for modulating inflammation in human diseases.
    Li W; Yuan J
    Front Immunol; 2023; 14():1159743. PubMed ID: 36969188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.